Mice with neuron-specific accumulation of mitochondrial DNA mutations show mood disorder-like phenotypes

Molecular Psychiatry

Volumn 11, Issue 6, 2006, Pages 577-593

  Kasahara, T ^a   Kubota, M ^a   Miyauchi, T ^a   Noda, Y ^b   Mouri, A ^b   Nabeshima, T ^b   Kato, T ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bipolar disorder; Chronic progressive external ophthalmoplegia; Circadian rhythm; Lithium; Mitochondria; POLG; Wheel running activity

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; LITHIUM; LITHIUM CARBONATE; MITOCHONDRIAL DNA; MOOD STABILIZER;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIPOLAR DISORDER; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; COMORBIDITY; CONTROLLED STUDY; DISEASE EXACERBATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ESTRUS CYCLE; FEMALE; FOREBRAIN; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC MODEL; MALE; MANIA; MENTAL DISEASE; MITOCHONDRIAL DEOXYRIBONUCLEIC ACID POLYMERASE GENE; MONOAMINE NERVE CELL; MOOD DISORDER; MOUSE; NERVE CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; TASK PERFORMANCE; TRANSGENIC MOUSE; TREADMILL;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIMANIC AGENTS; BEHAVIOR, ANIMAL; CIRCADIAN RHYTHM; DISEASE MODELS, ANIMAL; DNA, MITOCHONDRIAL; DNA-DIRECTED DNA POLYMERASE; FEMALE; GENE DELETION; LITHIUM CARBONATE; MALE; MICE; MICE, NEUROLOGIC MUTANTS; MICE, TRANSGENIC; MOOD DISORDERS; MOTOR ACTIVITY; NEURONS; OPHTHALMOPLEGIA, CHRONIC PROGRESSIVE EXTERNAL; PHENOTYPE; PROSENCEPHALON;

EID: 33745712834     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/sj.mp.4001824     Document Type: Article

References (69)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Text Revision (DSM-IV-TR), 2000.
2. Merikangas KR, Low NC. The epidemiology of mood disorders. Curr Psychiatry Rep 2004; 6: 411-421.
3. Goodwin FK, Jamison KR. Manic-Depressive Illness. Oxford University Press: New York, 1990.
4. Kato T, Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord 2000; 2: 180-190.
5. 7Li magnetic resonance spectroscopy. J Affect Disord 1993; 27: 53-59.
6. Kato T, Kunugi H, Nanko S, Kato N. Mitochondrial DNA polymorphisms in bipolar disorder. J Affect Disord 2001; 62: 151-164.
7. Munakata K, Tanaka M, Mori K, Washizuka S, Yoneda M, Tajima O et al. Mitochondrial DNA 3644T→C mutation associated with bipolar disorder. Genomics 2004; 84: 1041-1050.
8. Munakata K, Iwamoto K, Bundo M, Kato T. Mitochondrial DNA 3243A > G mutation and increased expression of LARS2 gene in the brains of patients with bipolar disorder and schizophrenia. Biol Psychiatry 2005; 57: 525-532.
9. Washizuka S, Iwamoto K, Kazuno A, Kakiuchi C, Mori K, Kametani M et al. Association of mitochondrial complex I subunit gene NDUFV2 at 18p11 with bipolar disorder in Japanese and the NIMH pedigrees. Biol Psychiatry 2004; 56: 483-489.
10. Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S et al. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 2004; 61: 300-308.
11. Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet 2005; 14: 241-253.
12. Krishnan KR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med 2005; 67: 1-8.
13. Siciliano G, Tessa A, Petrini S, Mancuso M, Bruno C, Grieco GS et al. Autosomal dominant external ophthalmoplegia and bipolar affective disorder associated with a mutation in the ANT1 gene. Neuromuscul Disord 2003; 13: 162-165.
14. Deschauer M, Hudson G, Muller T, Taylor RW, Chinnery PF, Zierz S et al. A novel ANT1 gene mutation with probable germline mosaicism in autosomal dominant progressive external ophthalmoplegia. Neuromuscul Disord 2005; 15: 311-315.
15. Spelbrink JN, Li FY, Tiranti V, Nikali K, Yuan Q-P, Tariq M et al. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet 2001; 28: 223-231.
16. Van Goethem G, Dermaut B, Löfgren A, Martin JJ, Van Broeckhoven C. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 2001; 28: 211-212.
17. Mancuso M, Filosto M, Bellan M, Liguori R, Montagna P, Baruzzi A et al. POLG mutations causing ophthalmoplegia, sensorimotor polyneuropathy, ataxia, and deafness. Neurology 2004; 62: 316-318.
18. Luoma P, Melberg A, Rinne JO, Kaukonen JA, Nupponen NN, Chalmers RM et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase γ mutations: clinical and molecular genetic study. Lancet 2004; 364: 875-882.
19. Van Goethem G, Löfgren A, Dermaut B, Ceuterick C, Martin J-J, Van Broeckhoven C et al. Digenic progressive external ophthalmoplegia in a sporadic patient: Recessive mutations in POLG and C10orf2/Twinkle. Hum Mutat 2003; 22: 175-176.
20. Suomalainen A, Majander A, Haltia M, Somer H, Lonnqvist J, Savontaus ML et al. Multiple deletions of mitochondrial DNA in several tissues of a patient with severe retarded depression and familial progressive external ophthalmoplegia. J Clin Invest 1992; 90: 61-66.
21. Van Goethem G, Luoma P, Rantamaki M, Al Memar A, Kaakkola S, Hackman P et al. POLG mutations in neurodegenerative disorders with ataxia but no muscle involvement. Neurology 2004; 63: 1251-1257.
22. Kato T, Stine OC, McMahon FJ, Crowe RR. Increased levels of a mitochondrial DNA deletion in the brain of patients with bipolar disorder. Biol Psychiatry 1997; 42: 871-875.
23. Kato T, Takahashi S, Shioiri T, Murashita J, Hamakawa H, Inubushi T et al. Reduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord 1994; 31: 125-133.
24. 31P-MR spectroscopy. Psychol Med 2000; 30: 107-115.
25. 31P MR spectroscopy in 28 patients with mitochondrial cytopathies. J Cereb Blood Flow Metab 1993; 13: 469-474.
26. Rango M, Bozzali M, Prelle A, Scarlato G, Bresolin N. Brain activation in normal subjects and in patients affected by mitochondrial disease without clinical central nervous system involvement: a phosphorus magnetic resonance spectroscopy study. J Cereb Blood Flow Metab 2001; 21: 85-91.
27. Dager SR, Friedman SD, Parow A, Demopulos C, Stoll AL, Lyoo IK et al. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry 2004; 61: 450-458.
28. Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry 2005; 10: 900-919.
29. Zhang D, Mott JL, Chang SW, Denniger G, Feng Z, Zassenhaus HP et al. Construction of transgenic mice with tissue-specific acceleration of mitochondrial DNA mutagenesis. Genomics 2000; 69: 151-161.
30. Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004; 429: 417-423.
31. Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, Wohlgemuth SE et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 2005; 309: 481-484.
32. Mayford M, Baranes D, Podsypanina K, Kandel ER. The 3′-untranslated region of CaMKIIα is a cis-acting signal for the localization and translation of mRNA in dendrites. Proc Natl Acad Sci USA 1996; 93: 13250-13255.
33. World Health Organization. ICD 10: International Statistical Classification of Diseases and Related Health Problems (10 version). Geneva, Switzerland, 1992.
34. Einat H, Manji HK, Belmaker RH. New approaches to modeling bipolar disorder. Psychopharmacol Bull 2003; 37: 47-63.
35. Machado-Vieira R, Kapczinski F, Soares JC. Perspectives for the development of animal models of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 209-224.
36. Miyamoto Y, Yamada K, Noda Y, Mori H, Mishina M, Nabeshima T et al. Lower sensitivity to stress and altered monoaminergic neuronal function in mice lacking the NMDA receptor ε4 subunit. J Neurosci 2002; 22: 2335-2342.
37. Ruf T. The Lomb-Scargle periodogram in biological rhythm: analysis of incomplete and unequally spaced time-series. Biol Rhythm Res 1999; 30: 178-201.
38. Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disord 2003; 5: 407-420.
39. Storlien LH, Higson FM, Gleeson RM, Smythe GA, Atrens DM. Effects of chronic lithium, amitriptyline and mianserin on glucoregulation, corticosterone and energy balance in the rat. Pharmacol Biochem Behav 1985; 22: 119-125.
40. Nelson JF, Felicio LS, Randall PK, Sims C, Finch CE. A longitudinal study of estrous cyclicity in aging C57BL/6J mice: I Cycle frequency, length and vaginal cytology. Biol Reprod 1982; 27: 327-339.
41. Carney SM, Goodwin GM. Lithium - a continuing story in the treatment of bipolar disorder. Acta Psychiatr Scand 2005; 111(Suppl 426): 7-12.
42. Bschor T, Lewitzka U, Sasse J, Adli M, Koberle U, Bauer M et al. Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms. Pharmacopsychiatry 2003; 36(Suppl 3): S230-S234.
43. Belke TW. Running and responding reinforced by the opportunity to run: effect of reinforcer duration. J Exp Anal Behav 1997; 67: 337-351.
44. Sherwin CM. Voluntary wheel running: a review and novel interpretation. Anim Behav 1998; 56: 11-27.
45. Daimon K, Yamada N, Tsujimoto T, Takahashi S. Circadian rhythm abnormalities of deep body temperature in depressive disorders. J Affect Disord 1992; 26: 191-198.
46. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000; 61(Suppl 6): 4-6.
47. Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998; 59(Suppl 14): 11-14.
48. Young LT, Warsh JJ, Kish SJ, Shannak K, Hornykeiwicz O. Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biol Psychiatry 1994; 35: 121-127.
49. Sobczak S, Honig A, van Duinen MA, Riedel WJ. Serotonergic dysregulation in bipolar disorders: a literature review of serotonergic challenge studies. Bipolar Disord 2002; 4: 347-356.
50. Blehar MC, DePaulo Jr JR, Gershon ES, Reich T, Simpson SG, Nurnberger Jr JI et al. Women with bipolar disorder: findings from the NIMH Genetics Initiative sample. Psychopharmacol Bull 1998; 34: 239-243.
51. Rasgon N, Bauer M, Grof P, Gyulai L, Elman S, Glenn T et al. Sex-specific self-reported mood changes by patients with bipolar disorder. J Psychiatr Res 2005; 39: 77-83.
52. Steiner M, Haskett RF, Osmun JN, Carroll BJ. Treatment of premenstrual tension with lithium carbonate. A pilot study. Acta Psychiatr Scand 1980; 61: 96-102.
53. Karadag F, Akdeniz F, Erten E, Pirildar S, Yucel B, Polat A et al. Menstrually related symptom changes in women with treatment-responsive bipolar disorder. Bipolar Disord 2004; 6: 253-259.
54. Perry W, Minassian A, Feifel D, Braff DL. Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania. Biol Psychiatry 2001; 50: 418-424.
55. Rich BA, Vinton D, Grillon C, Bhangoo RK, Leibenluft E. An investigation of prepulse inhibition in pediatric bipolar disorder. Bipolar Disord 2005; 7: 198-203.
56. Barrett SL, Kelly C, Watson DR, Bell R, King DJ. Normal levels of prepulse inhibition in the euthymic phase of bipolar disorder. Psychol Med 2005; 35: 1737-1746.
57. Ludewig S, Geyer MA, Ramseier M, Vollenweider FX, Rechsteiner E, Cattapan-Ludewig K et al. Information-processing deficits and cognitive dysfunction in panic disorder. J Psychiatry Neurosci 2005; 30: 37-43.
58. Simon NM, Otto MW, Wisniewski SR, Fossey M, Sagduyu K, Frank E et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2004; 161: 2222-2229.
59. Graziewicz MA, Longley MJ, Bienstock RJ, Zeviani M, Copeland WC. Structure-function defects of human mitochondrial DNA polymerase in autosomal dominant progressive external ophthalmoplegia. Nat Struct Mol Biol 2004; 11: 770-776.
60. Spelbrink JN, Toivonen JM, Hakkaart GA, Kurkela JM, Cooper HM, Lehtinen SK et al. In vivo functional analysis of the human mitochondrial DNA polymerase POLG expressed in cultured human cells. J Biol Chem 2000; 275: 24818-24828.
61. Luoma P, Melberg A, Rinne JO, Kaukonen JA, Nupponen NN, Chalmers RM et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase γ mutations: clinical and molecular genetic study. Lancet 2004; 364: 875-882.
62. Van Goethem G, Luoma P, Rantamaki M, Al Memar A, Kaakkola S, Hackman P et al. POLG mutations in neurodegenerative disorders with ataxia but no muscle involvement. Neurology 2004; 63: 1251-1257.
63. Hakonen AH, Heiskanen S, Juvonen V, Lappalainen I, Luoma PT, Rantamaki M et al. Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. Am J Hum Genet 2005; 77: 430-441.
64. Di Fonzo A, Bordoni A, Crimi M, Sara G, Del Bo R, Bresolin N et al. POLG mutations in sporadic mitochondrial disorders with multiple mtDNA deletions. Hum Mutat 2003; 22: 498-499.
65. Pozzan T, Magalhaes P, Rizzuto R. The comeback of mitochondria to calcium signalling. Cell Calcium 2000; 28: 279-283.
66. Soares JC, Mallinger AG. Intracellular phosphatidylinositol pathway abnormalities in bipolar disorder patients. Psychopharmacol Bull 1997; 33: 685-691.
67. Yamawaki S, Kagaya A, Okamoto Y, Shimizu M, Nishida A, Uchitoni Y. Enhanced calcium response to serotonin in platelets from patients with affective disorders. J Psychiatry Neurosci 1996; 21: 321-324.
68. Hahn C-G, Gomez G, Restrepo D, Friedman E, Josiassen R, Pribitkin EA et al. Aberrant intracellular calcium signaling in olfactory neurons from patients with bipolar disorder. Am J Psychiatry 2005; 162: 616-618.
69. Kasamatsu H, Robberson DL, Vinograd J. A novel closed-circular mitochondrial DNA with properties of a replicating intermediate. Proc Natl Acad Sci USA 1971; 68: 2252-2257.